ScreenPoint Medical is highlighting clinical results for Transpara, its breast AI software, at the European Society of Breast Imaging (EUSOBI) being held in Valencia, Spain.
One study published in Lancet Oncology in August found that Transpara-assisted workflow increased cancer detection by 20% and reduced reading workload by 44% with no change in recall rates.
Another study published in the Journal of Clinical Oncology in June found that using Transpara improved long-term risk prediction when its scoring system was combined with clinical risk factors for overall invasive cancers, screen-detected, advanced, and nonadvanced cancers, the company said.
